Vildagliptin was effective as add-on therapy in type 2 diabetes inadequately controlled with metformin monotherapy

摘要

The multicenter study by Bosi and colleagues is one of several recentlynpublished clinical trials (1) showing efficacy of dipeptidyl peptidasen(DPP)-4 inhibitors in improving glycemic control in type 2 diabetes.nThese studies have examined effects of DPP-4 inhibitors independentlynand in combination with metformin, sulphonylurea, or pioglitazonenand have shown up to a 1% decline in HbA1c levels. However, hardnclinical endpoints, such as changes in incidence of diabetic microvascularnand macrovascular complications, are clearly lacking, and furthernlong-term randomized trials are needed.